Individualized treatment with voriconazole in the Chinese population: Inflammation level as a novel marker for dose optimization

Abstract

AbstractAimsThe aim of this study was to explore the influence and possible mechanisms of pharmacokinetics‐related gene polymorphisms, especially CYP2C19 polymorphisms, and non‐genetic factors combined with the inflammatory status on the voriconazole (VRC) metabolism of the Chinese population.MethodsClinical studies were performed by collecting more than one VRC trough concentration and C‐reactive protein (CRP) level. A total of 265 blood samples were collected from 120 patients.ResultsResults of multiple regression analyses demonstrated that CYP2C19 genotypes and albumin (Alb) level remained predictors of Cminss/D in patients with no to mild inflammation (R2 = 0.12, P < .001). In addition, in patients with moderate to severe inflammation, it resulted in a significant model containing factors of CRP and total bilirubin (T‐Bil) levels (R2 = 0.19, P < .001). In non‐clinical studies, 32 rats were divided into control and inflammatory groups, and it was found that the mean residence time (MRT(0–t)) of VRC in the inflammatory group was significantly longer than that in the control group (P < .001), which may be due to down‐regulation of mRNA and protein expression of CYP2C19 (CYP2C6 in rats) through interleukin (IL)‐6/signal transducer and activator of transcription (STAT) 3 pathway.ConclusionsTherefore, the effect of CYP2C19 polymorphisms on VRC metabolism may be masked by inflammatory status, which should be of more concern than CYP2C19 polymorphisms in patients with moderate to severe inflammation. Additionally, the impact of Alb and T‐Bil on VRC metabolism should not be disregarded.